Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.74 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27533039 | 0.89 | ALDH1A1 (0.76) | TSHRALDH1A1LMNANPC1HPGD | |
| SCHEMBL16014465 | 0.82 | ALDH1A1 (0.70) | TSHRALDH1A1RIPK2LMNANPC1 | |
| SCHEMBL16014358 | 0.81 | TSHR (0.71) | TSHRALDH1A1LMNANPC1MAPK1 | |
| SCHEMBL4832108 | 0.80 | NPC1 (0.81) | TSHRALDH1A1LMNANPC1HPGD | |
| SCHEMBL17366533 | 0.80 | TSHR (0.57) | TSHRALDH1A1RIPK2LMNANPC1 | |
| SCHEMBL25325075 | 0.77 | ALDH1A1 (0.63) | TSHRALDH1A1LMNANPC1HPGD | |
| SCHEMBL16175848 | 0.77 | TSHR (0.78) | TSHRALDH1A1LMNANPC1HPGD | |
| SCHEMBL4349404 | 0.77 | ALDH1A1 (0.59) | TSHRALDH1A1LMNANPC1HPGD | |
| SCHEMBL174598 | 0.77 | TSHR (0.60) | TSHRALDH1A1RIPK2LMNANPC1 | |
| SCHEMBL16014599 | 0.76 | TSHR (0.53) | TSHRALDH1A1RIPK2LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105143220-B | Pyrazole derivatives | 豪夫迈·罗氏有限公司 | 2018-06-22 | — | — | CN | disclosed |
| US-9694012-B2 | Pyrazol derivatives | HOFFMANN-LA ROCHE INC. (US) | 2017-07-04 | — | — | US | disclosed |
| EP-2964646-B1 | NOVEL PYRAZOL DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2017-04-19 | — | — | EP | disclosed |
| US-20170035769-A1 | NOVEL PYRAZOL DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2017-02-09 | — | — | US | disclosed |
| US-9512132-B2 | Pyrazole compounds as CB2 agonists | HOFFMANN-LA ROCHE INC. (US) | 2016-12-06 | — | — | US | disclosed |
| EP-2964646-A1 | NOVEL PYRAZOL DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2016-01-13 | — | — | EP | disclosed |
| US-20150376192-A1 | NOVEL PYRAZOL DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2015-12-31 | — | — | US | disclosed |
| CN-105143220-A | Novel pyrazole derivatives | HOFFMANN LA ROCHE | 2015-12-09 | — | — | CN | disclosed |
| WO-2014135507-A1 | NOVEL PYRAZOL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-09-12 | — | — | WO | disclosed |
| US-20130303533-A1 | AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2013-11-14 | — | — | US | disclosed |
| EP-2611809-A1 | AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012030924-A1 | AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303533-A1 | AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | JAK3, JAK2, JAK1 | TSHR 2618/4885ALDH1A1 3689/4885RIPK2 132/4885 |
| US-20150376192-A1 | NOVEL PYRAZOL DERIVATIVES | CYP3A43, ADRB3, UGT1A3 | TSHR 1771/4885ALDH1A1 113/4885RIPK2 2682/4885 |
| US-20170035769-A1 | NOVEL PYRAZOL DERIVATIVES | CYP3A43, ADRB3, UGT1A3 | TSHR 1771/4885ALDH1A1 113/4885RIPK2 2682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.